Biotech company Polaryx Therapeutics reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for Investigational New Drug Application (IND) of PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL or CLN3).
JNCL or CLN3 is reportedly a rare and fatal genetic lysosomal storage disorder caused by a Cln3 gene mutation. CLN3 patients suffer from vision loss leading to blindness, seizures, progressive neurological deterioration, severe motor and cognitive declines and eventually death.
The company said PLX-200 is a repurposed drug that binds to the retinoid X receptor-α (RXRα), which binds to PPARα thereby up-regulating the expression of TPP1 mRNA in brain cells via the PPARα/RXRα heterodimer. PLX-200 activates PPARα, which enhances production of transcription factor EB (TFEB) in brain cells. PLX-200 also reduces inflammation and preventing cell death (apoptosis).
No drug is currently available to halt and/or delay the progression of the disease, concluded the company.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007